May 20, 2022
LONDON, May 20, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health...
Source URL: https://www.prnewswire.com:443/news-releases/lumiradx-receives-who-emergency-use-listing-for-sars-cov-2-ag-test-301551711.html
|
